-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: David Thomas, CFA
David is currently Director of Industry Research and Analysis at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry.
Latest Posts
State of the Industry – From BIO Investor Forum 2010
Here is our slide deck from the 9th annual BIO Investor Forum in San Francisco: BIO Investor Forum 2010 final From the media and blogosphere: Bloomberg in vivo blog Medical Technology Stock Letter
IPO update: 28 IPOs, 24 on Deck
The number of IPOs slowed during the summer, but the queue has been filling nicely. Fifteen more biotechs have filed to go public in the last month and a half, bringing the total to 24 globally. The two US IPOs this summer were from NuPATH and Trius. Again, we saw a reduction in the amount planned vs actually raised for these IPOs. On average, US biotechs have raised an amount 28% below what is first Read More >
1Q Cash Spending – Small Biotechs Still Spending Less
A comparison of cash spent on operations in the 1st quarter of 2010 vs the 1st quarters of 2009 and 2008 for small public biotechs shows a slowing in the precipitous drop seen over the last 2 years. However, the average small biotech is still spending less cash vs. 2008. When compared to 1Q08, the median cash flow from operations (CFO) in 1Q10 is down -40%. From 1Q09, median CFO is down -15%. See chart Read More >
Biotech Sector Performance Update 1H 2010
In my last update back in April, the broadest Biotech index (the 125 company Nasdaq Biotech Index, NBI) was up 11% for the year and ahead of just about every major sector. One quarter later things look a little different. The NBI is now down 5% and trailing 4 of the 10 S&P sectors (chart 1): However, the spotlight continues to shine on the AMEX Biotech Index (BTK). The BTK is up 8.6% for the Read More >
2010 BIO Business Forum Partnering Results
2010 BIO Business Forum in Chicago was a huge success last week. We hit record numbers for the three day event making this the single largest partnering event ever held. Our updated 1×1 partnering software system received over 107,000 requests for meetings that resulted in over 17,000 meetings. To put that in perspective, 10 years ago there were only 300 meetings, yielding an explosive 43% CAGR for partnering at the BIO International Convention. The meetings were set up by some 2,100 Read More >
